kidney issues with tirzepatide Renal effects of GLP-1 receptor agonists and in individuals type 2 diabetes: seeds of a promising future | Endocrine SURPASS-CVOT: Tirzepatide Significantly Reduces Major

Attenuation by gastric pentadecapeptide BPC 157, cimetidine, ranitidine, atropine, omeprazole, sulphasalazine and methylprednisolone

Fox Foundation provided study funding

Patients are often compound heterozygote with a combination that includes at least one novel mutations or VUS

These results held true across multiple dose levels and treatment durations, suggesting sustained benefit without unexpected toxicity patterns

References Dauer, W

The compounded products available as part of our Weight Loss Program are not made by Novo Nordisk, Eli Lilly or Amylin Pharmaceuticals or any company affiliated with Novo Nordisk, Eli Lilly or Amylin Pharmaceuticals.